Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.

Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A

Fertility and sterility1 Feb 2006Cited by 100 (Europe PMC)

PMID16595206DOI10.1016/j.fertnstert.2005.07.1315PepBankPUB-16595206

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing four of five symptoms or signs at month 6.
In plain wordsIn women with endometriosis, leuprolide and DMPA-SC similarly reduced four of five symptoms or signs at month 6.
Peptide
Leuprolide
Outcome
No significant changeFour endometriosis symptoms or signs at month 6
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
3 context sentences(design, population, supporting numbers)
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520601
02HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing dysmenorrhea at month 18.
In plain wordsLeuprolide and DMPA-SC similarly reduced menstrual pain at month 18 in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changeDysmenorrhea at month 18
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
4 context sentences(design, population, supporting numbers)
Summary · context
Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520602
03HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing dyspareunia at month 18.
In plain wordsLeuprolide and DMPA-SC similarly reduced pain during intercourse at month 18 in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changeDyspareunia at month 18
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
4 context sentences(design, population, supporting numbers)
Summary · context
Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520603
04HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing pelvic pain at month 18.
In plain wordsLeuprolide and DMPA-SC similarly reduced pelvic pain at month 18 in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changePelvic pain at month 18
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
4 context sentences(design, population, supporting numbers)
Summary · context
Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520604
05HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing pelvic tenderness at month 18.
In plain wordsLeuprolide and DMPA-SC similarly reduced pelvic tenderness at month 18 in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changePelvic tenderness at month 18
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
4 context sentences(design, population, supporting numbers)
Summary · context
Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520605
06HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA-SC were equivalent for reducing pelvic induration at month 18.
In plain wordsLeuprolide and DMPA-SC similarly reduced pelvic induration at month 18 in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changePelvic induration at month 18
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18).
4 context sentences(design, population, supporting numbers)
Summary · context
Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520606
07HumanRandomized controlled trialSafety outcome
In women with endometriosis, leuprolide was associated with more bone mineral density loss than DMPA-SC at month 6.
In plain wordsWomen with endometriosis lost more bone density with leuprolide than with DMPA-SC at month 6.
Peptide
Leuprolide
Outcome
IncreaseBone mineral density loss at month 6
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Bone and joint · Musculoskeletal
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
Patients in the DMPA-SC 104 group showed significantly less BMD loss than did leuprolide patients at month 6, with scores returning to baseline at 12 months' follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520607
08HumanRandomized controlled trialSafety outcome
In women with endometriosis, median weight changes did not differ significantly between leuprolide and DMPA-SC.
In plain wordsWeight changes did not differ significantly between leuprolide and DMPA-SC in women with endometriosis.
Peptide
Leuprolide
Outcome
No significant changeMedian weight change
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Body weight · Metabolic and weight
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
No statistically significant differences in median weight changes were observed between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520608
09HumanRandomized controlled trialSafety outcome
In women with endometriosis, leuprolide was associated with more hypoestrogenic symptoms than DMPA-SC.
In plain wordsWomen with endometriosis had more low-estrogen symptoms with leuprolide than with DMPA-SC.
Peptide
Leuprolide
Outcome
IncreaseHypoestrogenic symptoms
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Adverse events · Endocrine and hormones
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared with leuprolide, DMPA-SC 104 was associated with fewer hypoestrogenic symptoms but more irregular bleeding.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520609
10HumanRandomized controlled trialSafety outcome
In women with endometriosis, leuprolide was associated with less irregular bleeding than DMPA-SC.
In plain wordsWomen with endometriosis had less irregular bleeding with leuprolide than with DMPA-SC.
Peptide
Leuprolide
Outcome
DecreaseIrregular bleeding
Study
n = 274
Comparator
DMPA-SC 104
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared with leuprolide, DMPA-SC 104 was associated with fewer hypoestrogenic symptoms but more irregular bleeding.
3 context sentences(design, population, supporting numbers)
Summary · context
Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.
Summary · context
Two hundred seventy-four women with surgically diagnosed endometriosis.
Summary · context
Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.
Report a problemFND-1659520610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.